What is Personalised Microbial Intervention?
The term ‘Personalised Microbial Intervention’ has been bandied around in health and fitness circles recently, but what does it actually mean? We thought we would try to explain…
Firstly, let’s take a little walk back in time to the dawn of probiotic research: surprising as it may seem, the potential power of probiotics was recognised over a century ago, but has been somewhat buried under the avalanche of pharmaceutical research that has preoccupied medical science for the past few decades. The world was so keen to embrace and run with the antibiotic revolution that we forgot that we had our own internal army of immune-boosting defenders already onboard, until an interest in the hidden world within our intestines re-surfaced in the latter part of the last century.
Building on embryonic work by Russian scientist Metchnikoff, one of the first scientists to recognise the potential health-giving properties of our intestinal flora1, and suggested that we may be able positively influence health and combat the aging process by careful manipulation of gut bacteria, this renewed focus on the human microbiome has determined that it may have such far-reaching effects within the body, that some professionals claim that it should be considered to be an organ in its own right2.
What is even more astonishing and exciting is that, within the myriad species of bacteria we support, the emerging evidence is suggesting that each different species – and the different strains within that species – may have its own unique effect on our health and well-being, in a symbiotic relationship that benefits both resident and host.
P M I – one probiotic does NOT fit all
Those of us who trained in the field of naturopathy or nutritional therapy many years ago would not have had the benefit of realising that, when recommending a probiotic to patients, one size – or strain – does NOT necessarily fit all. It is this concept which is now revolutionising the probiotic world and, whilst overall gut health may be a key factor in the development of many diseases, and the use of broad-strain probiotic formulations definitely have their place in rebalancing the gut flora, it is becoming possible to tailor the probiotic supplement protocols to incorporate specific strains to address specific health and digestive conditions: personalised microbial intervention.
We’re delighted that one of the most respected therapists in the field of nutritional therapy, Antony Haynes, has recognised and embraced the potential of ‘personalised microbial intervention’. In a lovely piece recently published in the Natural Dispensary magazine3, Haynes wrote:
‘Wouldn’t it be incredible if science could identify within the millions and billions of bacteria, that specific strains have specific actions, leading to definitive positive health outcomes?’
Wouldn’t it indeed? In fact, it’s already been done!
Ahem, we’ve been shouting about ‘Strain specificity’ for years now, and it’s a concept that underpins our entire product range. See ‘Our Probiotic Strains’ for a more in-depth look at the classification of bacteria, and how it’s the strain and not just the species that’s a key consideration when it comes to choosing the right probiotic.
Not only that, but the ‘science’ is already there to substantiate this, and our entire product range is supported by the results of clinical trials; in fact, we have significantly more clinical trials on our finished products than any other live cultures brand available in the UK. See our blog, Most researched probiotics: comparing brands for more information.
Many practitioners already use our products for their patients, confident in the knowledge that they can provide ‘personalised microbial intervention’ by recommending the correct strains of bacteria for their clients’ individual health conditions.
It’s been possible to identify strains that provide benefit in many, often unexpected, ways; in particular, specific strains of probiotics which have been shown to significantly reduce cholesterol. The three strains of bacteria, Lactobacillus plantarum CECT 7527, Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 752, were used in combination in a randomised, double-blind and placebo-controlled clinical trial and shown to significantly reduce total cholesterol by 0.9 mmol/L (14%) after a three month period4.
Though they can be life-savers in some situations, antibiotics have an indiscriminate action which may severely disrupt the delicate balance of the intestinal flora. This can lead to unpleasant side effects and post-treatment digestive issues, but again there is some strain-specific help at hand. Lactobacillus rhamnosus Rosell-11 and Lactobacillus acidophilus Rosell-52 are very hardy strains of bacteria which are not affected by the action of antibiotics, and so can help to prevent unpleasant antibiotic-associated symptoms and keep the flag flying for our friendly flora throughout the course of medication.
We have amongst our microbial arsenal some of the world’s most researched probiotic strains, many of which have been featured in ‘gold-standard’ clinical trials.
Saccharomyces boulardii is certainly one of the most studied species, and this diarrhoea-calming, anti-inflammatory, gut-healing, pathogen-clearing probiotic yeast is registered as a medicine in many countries around the world.
Bifidobacterium lactis BB-12® was recently featured in possibly the largest ever clinical trial on probiotics, where it was shown to promote bowel regularity. Read more about this research here: Largest ever probiotic trial supports BB-12 for regularity.
Two strains of probiotics – Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14® - have been formulated based on the results of more than 30 years of scientific research. These two strains pass through the intestines to colonise in the genitor-urinary tract within 3-4 days of oral consumption. Clinical trials using over 2,500 female subjects demonstrated the efficacy of this probiotic combination against thrush, cystitis and bacterial vaginosis - practitioners can find research on the Probiotics Database.
So, where do we go next to fine-tune PMI for your patients? Well, research is still emerging, and we constantly monitor the latest progress made in probiotic research, in order to ensure that we offer a range based on credible evidence and solid results.
PMI could utilise our microbiomic ‘fingerprint’
The field of probiotic research has now advanced to the level where it is claimed we can all be identified according to our unique microbial profile which, in a study conducted at the Harvard T.H. Chan School of Public Health this year, was claimed to be as individual as our fingerprints5. If our intestinal flora is so unique, then surely each individual needs an unique combination of strains to rebalance their gut bacteria, and their health?
Well, we haven't quite reached that level of supplemental sophistication, but who knows whether, in the future, science will provide practitioners with the tools to offer each patient a comprehensive profile of their gut microbiota, and then put together a personalised probiotic pill containing exactly the strains of bacteria they need to rebalance their health. Until that time, if you want to offer your patients PMI, you’ll agree that our product range is the closest thing!
For more information about our range of strain-specific products, and the science that supports them, click on these links:
1. Mackowiak, (2013), ‘Recycling Metchnikoff: Probiotics, the Intestinal Microbiome and the Quest for Long Life’, Frontiers Public Health. 2013; 1: 52.
2. O'Hara & Shanahan (2006) The gut flora as a forgotten organ, EMBO Rep. 2006 Jul; 7(7): 688–693.
3. A. Haynes (2015), Personalised Microbial Intervention, 'Only Natural', Autumn:4-5.
4. Full trial: Fuentes MC et al. (2006) Cholesterol¬ lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. British Journal of Nutrition; pp 1 - 7.
5. Franzosa et al, (2015) ‘Identifying personal microbiomes using metagenomics codes’ PNAS, online May 11, 2015 doi:10.1073/pnas.1423854112